Interv Akut Kardiol 2011; 10(5-6): 226-230

Bleeding complications of percutaneous coronary interventions

Martin Novák
I. interní kardioangiologická klinika, FN u sv. Anny v Brně

Percutaneous coronary intervention is crucial to the treatment of coronary artery disease. Invasive nature of procedure in conjunction

with the use of antithrombotics means the risk of bleeding that is associated with worse ischemic outcomes and increased short-time

as well as long-time mortality. Optimalization of pharmacotherapy and use of radial artery access reduce bleeding rates and together

with restrictive use of blood transfusions improve patient outcomes.

Keywords: coronary intervention, bleeding complication, blood transfusion, radial artery access

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novák M. Bleeding complications of percutaneous coronary interventions. Interv Akut Kardiol. 2011;10(5-6):226-230.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100: 1364-1369. Go to original source... Go to PubMed...
    2. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-935. Go to original source... Go to PubMed...
    3. Doyle BJ, Ting HH, Bell MR, et al. Major femoral bleeding complications after percutaneous coronary intervention: incidence, predictors, and impact on long-term survival among 17,901 patients treated at the Mayo Clinic from 1994 to 2005. JACC Cardiovasc Interv 2008; 1: 202-209. Go to original source... Go to PubMed...
    4. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 2006; 355: 2203-2216. Go to original source... Go to PubMed...
    5. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 2008; 358: 2218-2230. Go to original source... Go to PubMed...
    6. Omar Farouque HM, et al. Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure device. J Am Coll Cardiol, 2005; 45: 363-368. Go to original source... Go to PubMed...
    7. Abbas AE, Brodie B, Dixon S, et al. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 96: 173-176. Go to original source... Go to PubMed...
    8. Chin MW, Yong G, Bulsara MK, et al. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 2007; 102: 2411. Go to original source... Go to PubMed...
    9. Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54: 1293-1302. Go to original source... Go to PubMed...
    10. Gaglia MA Jr, Torguson R, Gonzalez MA, et al. Correlates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention. Am J Cardiol 2010; 106: 1069-1074. Go to original source... Go to PubMed...
    11. Yatskar L, Selzer F, Feit F, et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv 2007; 69: 961-966. Go to original source... Go to PubMed...
    12. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697. Go to original source... Go to PubMed...
    13. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106: 2605-2612. Go to original source... Go to PubMed...
    14. Taylor JE, Henderson IS, Stewart WK, Belch JJ. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991; 338: 1361-1362. Go to original source... Go to PubMed...
    15. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59: 538-548. Go to original source... Go to PubMed...
    16. Hebert PC, McDonald BJ, Tinmouth A. Clinical consequences of anemia and red cell transfusion in the critically ill Crit Care Clin 2004; 20: 225-235. Go to original source... Go to PubMed...
    17. Doyle BJ, et al. Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention. J Am Coll Cardiol, 2009; 53: 2019-2027. Go to original source... Go to PubMed...
    18. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion Ann Intern Med 1992; 116: 393-402. Go to original source... Go to PubMed...
    19. Twomley KM, Rao SV, Becker RC. Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions J Thromb Thrombolysis 2006; 21: 167-174. Go to original source... Go to PubMed...
    20. Van de Werf F, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal 2008; 29: 2909-2945. Go to original source... Go to PubMed...
    21. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961-966. Go to original source... Go to PubMed...
    22. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N. Engl. J. Med. 2006; 355: 1006-1017. Go to original source... Go to PubMed...
    23. Alexander KP, et al. Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes JAMA 2005; 294(24): 3108-1316. Go to original source... Go to PubMed...
    24. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696. Go to original source... Go to PubMed...
    25. Stabile E, Nammas W, Salemme L, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J. Am. Coll. Cardiol. 2008; 52: 1293-1298. Go to original source... Go to PubMed...
    26. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. Go to original source... Go to PubMed...
    27. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057. Go to original source... Go to PubMed...
    28. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329. Go to original source... Go to PubMed...
    29. Brasselet C, et al. Comparison of operator radiation exposure with optimized radiation protection devices during coronary angiograms and ad hoc percutaneous coronary interventions by radial and femoral routes. Eur Heart J 2008; 29: 63-70. Go to original source... Go to PubMed...
    30. Jolly SS, et al. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials. Am Heart J 2009; 157: 132-140. Go to original source... Go to PubMed...
    31. Jolly SS, et al. Radial vesus femoral access for coronary angiography or intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377: 1409-1420. Go to original source... Go to PubMed...
    32. Urban P, et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population. J Am Coll Cardiol, 2011; 57: 1445-1454. Go to original source... Go to PubMed...
    33. Young JJ, Choo JK, Kereiakes DJ. Platelet Glycoprotein IIb/IIIa Inhibition in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction: Application of the ACC/AHA Guidelines.J Invasive Cardiol. 2003; 15(2). Go to original source...
    34. Chassot PG, et al. Perioperative antiplatelet therapy: The case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99: 316-328. Go to original source... Go to PubMed...
    35. Doyle BJ, et al. Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention. Implications for Contemporary Practice. JACC, 2009; 2019-2027. Go to original source... Go to PubMed...
    36. Robinson SD, et al. Red Blood Cell Storage Duration and Mortality in Patients Undergoing Percutaneous Coronary Intervention. Am Heart J, 2010; 159(5): 876-881. Go to original source... Go to PubMed...
    37. White HD, et al. Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?. Curr Opin Cardiol. 2011; 26(4): 275-278. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.